Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

Open access
The EMPA-KIDNEY Collaborative Group, Herrington, William G, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen, Staplin, Natalie, Preiss, David, Stevens, Will, Wallendszus, Karl, Dayanandan, Rejive, Knott, Carol, Hill, Michael, Emberson, Jonathan, Brenner, Susanne, Cejka, Vladimir, Cheung, Alfred K, Liu, Zhihong, Li, Jing, Chen, Peiling, Hooi, Laiseong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Pontremoli, Roberto, Maggioni, Aldo Pietro, Goto, Shinya, Tomita, Aiko, Deo, Rajat, Tuttle, Katherine, Eilbracht, Jens, Hantel, Stefan, Hopley, Mark, Landray, Martin J, Baigent, Colin, Haynes, Richard, Baigent, Colin, Landray, Martin J, Wanner, Christoph, Herrington, William G, Haynes, Richard, Green, Jennifer B, Hauske, Sibylle J, Brueckmann, Martina, Hopley, Mark, Brenner, Susanne, Cheung, Alfred K, Preiss, David, Liu, Zhihong, Li, Jing, Hooi, Laiseong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Pontremoli, Roberto, Maggioni, Aldo Pietro, Staplin, Natalie, Emberson, Jonathan, Hantel, Stefan, Goto, Shinya, Deo, Rajat, Tuttle, Katherine, Ng, Sarah Y A, Lozano, Francisco Javier Rossello, Sammons, Emily, Zhu, Doreen, Sandercock, Peter, Bilous, Rudolf, Herzog, Charles, Whelton, Paul, Wittes, Janet, Bennett, Derrick, Burke, Andy, Brown, Richard, Dayanandan, Rejive, Fletcher, Lucy, Gosling, Hannah, Harding, Emily, Haynes, Richard, Herrington, William G, Judge, Parminder, Knott, Carol, Lee, Ryonfa, Murphy, Kevin, Qiao, Yanru, Raff, Rachel, Yu, Hui, Qiao, YanRu, Cejka, Vladimir, Fajardo-Moser, Marcela, Lorimer, Andrea, Lucci, Donata, Hepditch, Anita, Axler, Amanda, Chen, Peiling, Hao, Dai, Goh, Cheng Beng, Sivanandam, Sarojini, Hashimoto, Akiko, Negoro, Wakako, Tomita, Aiko, Tomoko, Morisaki · 2022 · Nephrology Dialysis Transplantation

Abstract

Background: The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). Methods: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD. People with or without diabetes mellitus (DM) were eligible provided they had an estimated glomerular filtration rate (eGFR) ≥20 but <45 mL/min/1.73 m2 or an eGFR ≥45 but <90 mL/min/1.73 m2 with a urinary albumin:creatinine ratio (uACR) ≥200 mg/g. The trial design is streamlined, as extra work for collaborating sites is kept to a minimum and only essential information is collected. Results: Between 15 May 2019 and 16 April 2021, 6609 people from eight countries in Europe, North America and East Asia were randomized. The mean age at randomization was 63.8 years [standard deviation (SD) 13.9)], 2192 (33%) were female and 3570 (54%) had no prior history of DM. The mean eGFR was 37.5 mL/min/1.73 m2 (SD 14.8), including 5185 (78%) with an eGFR <45 mL/min/1.73 m2. The median uACR was 412 mg/g) (quartile 1–quartile 3 94–1190), with a uACR <300 mg/g in 3194 (48%). The causes of kidney disease included diabetic kidney disease [n = 2057 (31%)], glomerular disease [n = 1669 (25%)], hypertensive/renovascular disease [n = 1445 (22%)], other [n = 808 (12%)] and unknown causes [n = 630 (10%)]. Conclusions: EMPA-KIDNEY will evaluate the efficacy and safety of empagliflozin in a widely generalizable population of people with CKD at risk of kidney disease progression. Results are anticipated in 2022.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfac040

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphic abstract
Graphic abstract CC BY · PubMed Central
Figure 1 EMPA-KIDNEY key outcomes.
Figure 1 EMPA-KIDNEY key outcomes.CC BY · PubMed Central
Figure 2 Inclusion and exclusion criteria for entry into the EMPA-KIDNEY trial.
Figure 2 Inclusion and exclusion criteria for entry into the EMPA-KIDNEY trial.CC BY · PubMed Central
Figure 3 Trial profile—flow of participants through EMPA-KIDNEY trial recruitment.
Figure 3 Trial profile—flow of participants through EMPA-KIDNEY trial recruitment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 1

  1. United States Renal Data System, 2014, 2014 Annual Data Report: Atlas of End-stage Renal Disease in the United States

Cited by

See all 119

Metadata

Authors
The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Wanner, C., Green, J. B., Hauske, S. J., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., Staplin, N., Preiss, D., Stevens, W., Wallendszus, K., Dayanandan, R., Knott, C., Hill, M., Emberson, J., Brenner, S., Cejka, V., Cheung, A. K., Liu, Z., Li, J., Chen, P., Hooi, L., Liu, W., Kadowaki, T., Nangaku, M., Levin, A., Cherney, D., Pontremoli, R., Maggioni, A. P., Goto, S., Tomita, A., Deo, R., Tuttle, K., Eilbracht, J., Hantel, S., Hopley, M., Landray, M. J., Baigent, C., Haynes, R., Baigent, C., Landray, M. J., Wanner, C., Herrington, W. G., Haynes, R., Green, J. B., Hauske, S. J., Brueckmann, M., Hopley, M., Brenner, S., Cheung, A. K., Preiss, D., Liu, Z., Li, J., Hooi, L., Liu, W., Kadowaki, T., Nangaku, M., Levin, A., Cherney, D., Pontremoli, R., Maggioni, A. P., Staplin, N., Emberson, J., Hantel, S., Goto, S., Deo, R., Tuttle, K., Ng, S. Y. A., Lozano, F. J. R., Sammons, E., Zhu, D., Sandercock, P., Bilous, R., Herzog, C., Whelton, P., Wittes, J., Bennett, D., Burke, A., Brown, R., Dayanandan, R., Fletcher, L., Gosling, H., Harding, E., Haynes, R., Herrington, W. G., Judge, P., Knott, C., Lee, R., Murphy, K., Qiao, Y., Raff, R., Yu, H., Qiao, Y., Cejka, V., Fajardo-Moser, M., Lorimer, A., Lucci, D., Hepditch, A., Axler, A., Chen, P., Hao, D., Goh, C. B., Sivanandam, S., Hashimoto, A., Negoro, W., Tomita, A., & Tomoko, M.
Venue
Nephrology Dialysis Transplantation
Published
2022-03-03
Volume
37
Issue
7
Pages
1317-1329
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W4213426937
Cited by
110
References
52
Citations by year
2026: 6 · 2025: 13 · 2024: 23 · 2023: 33 · 2022: 35
FWCI
16.48
Type
journal article
Language
en
Open access
Locations
  • Nephrology Dialysis Transplantation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Boehringer Ingelheim
  • Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
empagliflozin, SGLT2 inhibitors, chronic kidney disease, kidney disease progression, cardiovascular mortality, diabetic nephropathy, glomerular disease, estimated glomerular filtration rate, urinary albumin-creatinine ratio, trial recruitment, trial design, EMPA-KIDNEY trial, diabetes mellitus
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Kidney, Male, Randomized Controlled Trials as Topic, Disease Progression, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. https://app.cochat.ai/papers/10.1093/ndt/gfac040
The paper
The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Wanner, C., Green, J. B., Hauske, S. J., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., Staplin, N., Preiss, D., Stevens, W., Wallendszus, K., Dayanandan, R., Knott, C., Hill, M., Emberson, J., Brenner, S., . . . Tomoko, M. (2022). Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac040

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.